Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PaushakBOM:532742 -1.92%79 EBITDA Margin % is 34.47% as of Jun. 2026, which is 8% below its 10-year median of 37.55. GuruFocus rates BOM:532742 with a GF Score™ of 79/100 and a GF Value™ of ₹759.66 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,585 Chemicals companies, Paushak ranks better than 94.76% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Paushak's EBITDA for the
three
months ended in Jun. 2026 was ₹288 Mil. Paushak's Revenue for the
three
months ended in Jun. 2026 was ₹836 Mil. Therefore, Paushak's EBITDA margin for the quarter that ended in Jun. 2026 was 34.47%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Paushak EBITDA Margin % Related Terms
Paushak EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Paushak's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532742 vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Paushak's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paushak EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Paushak's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Paushak's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paushak (BOM:532742) has a EBITDA Margin % of 34.47% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Paushak and its competitors. This is near median its historical median of 37.55. Over the past decade, Paushak's EBITDA Margin % has ranged from 26.34 to 41.47. According to the industry distribution chart, Paushak ranks #83 out of 1585 companies in the Chemicals industry, placing it in the top 5.2%.
Is Paushak's EBITDA Margin % too high?
Paushak's current EBITDA Margin % of 34.47% is near median its 10-year median of 37.55. Over the past 10 years, this metric has ranged from a low of 26.34 to a high of 41.47. The Chemicals industry median EBITDA Margin % is 10.54. Paushak's value of 34.47% is 227% above this industry median. Based on the distribution chart, Paushak ranks #83 out of 1585 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Paushak has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Paushak's EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Paushak ranks #83 out of 1585 companies for EBITDA Margin %. This places Paushak in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.54. Paushak's value of 34.47% is 227% above this benchmark. Historically, Paushak's own EBITDA Margin % has ranged from 26.34 to 41.47 over the past decade. While the company's 10-year median is 37.55 vs. the industry median of 10.54, Paushak has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 10.54, based on 1,585 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paushak's current EBITDA Margin % of 34.47% is 227% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Paushak and its competitors. For the Chemicals industry, the median EBITDA Margin % is 10.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paushak's current EBITDA Margin % is 34.47%, which is near median its own 10-year median of 37.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paushak stock overvalued right now?
Based on GuruFocus' analysis, Paushak (BOM:532742) is currently considered Fairly Valued. The stock's GF Value™ is ₹759.66, compared to a current price of ₹736.40 — trading 3.1% below its estimated fair value. The current EBITDA Margin % is 34.47%, which is near median its 10-year median of 37.55 and 227% above the Chemicals industry median of 10.54. Paushak's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Paushak (BOM:532742), the current EBITDA Margin % is 34.47% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paushak (BOM:532742) Overvalued in 2026?
Based on GuruFocus' analysis, Paushak stock appears to be undervalued.
The current stock price of ₹736.40 is trading 3.1% below its estimated GF Value™ of ₹759.66.
GuruFocus considers Paushak to be Fairly Valued.
Key valuation signals for BOM:532742:
EBITDA Margin %: 34.47% (near median its 10-year median of 37.55)
GF Value™: ₹759.66 vs. price of ₹736.40 (3.1% below fair value)
Industry Position: 227% above the Chemicals median (#83 of 1585)
No single metric tells the full story. See the BOM:532742 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paushak Ltd manufactures and develops phosgene-based specialty chemicals and intermediates. The company operates in only one segment, Speciality chemicals. It produces Isocyanates such as 2-Phenyl Ethyl isocyanate, Cyclohexyl isocyanate; Chloroformates which include Benzyl chloroformate, 2- Ethylhexyl chloroformate, Isobutyl chloroformate and Carboamoyl Chlorides such as Diethylcarbamoyl Chloride, and N-Ethyl-N-Methylcarbamoyl Chloride and others. Geographically, the company has a business presence in India and outside India, from which a majority of its revenue is derived within India.
79GF Score
Get the complete analysis for BOM:532742
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532742 has been successfully added to your 
